Amanta Healthcare lists at ₹135 on NSE, a 7% premium over IPO price

Amanta Healthcare, the Gujarat-based pharmaceutical company, made its stock market debut today, 9 September 2025. On NSE, the stock opened at ₹135 per share, marking a 7.14% premium over its issue price of ₹126. On the Bombay Stock Exchange (BSE), shares listed at ₹134, up 6.35% from the issue price. 

For retail investors who were allotted shares, the listing translates to a gain of ₹1,071 per lot of 119 shares at the upper price band of ₹126. 

Amanta Healthcare IPO Details

Amanta Healthcare had launched its Initial Public Offering (IPO) with a price band of ₹120–₹126 per share, aiming to raise ₹126 crore through a fresh issue of 1 crore equity shares. 

The IPO witnessed overwhelming investor interest across all categories, with the issue oversubscribed by 82.61 times. Non-institutional investors (NIIs) led the subscription at 209.42 times, followed by retail individual investors (RIIs) at 54.98 times and qualified institutional buyers (QIBs) at 35.86 times.

The company intends to use the IPO proceeds to fund capital expenditure for civil construction and to purchase equipment, plants, and machinery for establishing a new SteriPort manufacturing line at Hariyala, Kheda, Gujarat, and setting up a new SVP manufacturing line at the same location. Remaining funds will be used for general corporate purposes. 

About Amanta Healthcare

Amanta Healthcare is a pharmaceutical company that develops, manufactures and markets a diverse range of sterile liquid products and large volume parenterals (“LVPs”) and small volume parenterals (“SVPs”) in six therapeutic segments. Along with this, the company also manufactures medical devices, fluid therapy (IV fluid) formulations, diluents, ophthalmic products, etc. 

Disclaimer: This news is solely for educational purposes. The securities/investments quoted here are not recommendatory.

To read the RA disclaimer, please click here